Laura CressTechnology reporter
Getty ImagesThe UK will bring into force a law which will make it illegal to create non-consensual intimate images, following widespread concerns over Elon Musk’s Grok AI chatbot.
The Technology Secretary Liz Kendall…
SEATTLE — Jan. 12, 2026 — Fred Hutch Cancer Center welcomed Sabah Öney to its Board of Directors effective Jan. 1, 2026. Öney is the president and chief executive officer of Dispatch Bio, a start-up company that is engineering a universal treatment across solid tumors.
“It is an honor to join the Fred Hutch Board of Directors,” said Öney. “For the past 50 years, Fred Hutch has built a global reputation for developing lifesaving treatments and leading scientific innovation, and I look forward to joining with this outstanding group of leaders to advance the mission of curing cancer and infectious diseases.”
Öney brings nearly 20 years of scientific experience and executive leadership in the biotechnology industry. In 2012, he oversaw the global expansion of products at Ariosa Diagnostics. Later, he served as the Chief Business Officer of Alector, a biotech company leveraging the immune system against neurodegenerative diseases and guided the company throughout its IPO process. In 2021, he joined ARCH Venture Partners as a Venture Partner. Öney is also a Co-founder and Interim CEO of Vilya, a computational biotechnology company founded by Nobel Laureate David Baker, PhD, and serves on its Board of Directors.
His education experience reflects a combination of scientific innovation and business experience. Öney received his bachelor’s degree in genetics from the University of Kansas, his MBA from Stanford University Graduate School of Business and his PhD in Genetics and Genomics from Duke University. He is the co-author of numerous scientific publications and has developed several biotechnology patents.
Motivated both professionally and personally to advance immunotherapy treatment and research, Öney shares a passion for Fred Hutch’s mission to eliminate cancer and infectious diseases. In 2022, as part of Fred Hutch’s Climb to Fight Cancer Timmerman Traverse trek to the Everest Base Camp, he raised nearly $97,000 for cancer research at Fred Hutch and called the journey a “life-altering experience.”
“Sabah is an outstanding addition to our Board of Directors, bringing a wealth of experience in leading innovative biotechnology companies that are transforming the treatment of cancer and other diseases,” said Dr. Thomas J. Lynch, president and director of Fred Hutch and holder of the Raisbeck Endowed Chair. “As we now enter the next 50 years of Fred Hutch’s mission and legacy, Sabah’s insight will be instrumental in advancing our next chapter of scientific innovation and treatment.”
###
Media contact:
Shayla Ring
sring@fredhutch.org
Fred Hutch Cancer Center unites individualized care and advanced research to provide the latest cancer treatment options while accelerating discoveries that prevent, treat and cure cancer and infectious diseases worldwide.
Based in Seattle, Fred Hutch is an independent, nonprofit organization and the only National Cancer Institute-designated cancer center in Washington. We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, immunotherapy, HIV/AIDS prevention and COVID-19 vaccines. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services. Fred Hutch also serves as UW Medicine’s cancer program.
A tree trunk can host microbes that remove greenhouse and toxic gases, adding an air-cleaning role beyond carbon dioxide uptake.
In a five-year survey across eastern Australia, researchers traced this work to microbes living in bark.
Researchers at the University of California, Davis, have uncovered new details about how a once-deadly coronavirus disease in cats spreads through the immune system. The findings may help scientists better understand long COVID and other…
NASA will undock a SpaceX Dragon capsule from the International Space Station and bring four astronauts home Thursday morning after a medical problem prompted an early return.
The move…
One cyclist, Nathan, who works at York Hospital, said he has seen a number of people admitted due to their bikes tripping over the “sausages”.
“The council needs to come back and finish the sausage job. It’s pitch black down here at 6am,” he…
Seven Pakistani police officers were killed in a targeted bomb blast on their armoured vehicle on Monday (January 12, 2026), police in the northwestern Tank district said, as Islamabad contends with a rising wave of militancy.
Images of…
Global law firm Squire Patton Boggs is pleased to announce that partners Charles Leeming (London), Traci Martinez (Columbus), and Galileo Pozzoli (Milan) have been elected by the firm’s partners to serve on the Global Board.
“In a time of dramatic geopolitical change and rapid technological advancements, the need to deliver premier integrated legal and policy solutions has never been greater,” said Chair and Global CEO Mark Ruehlmann. “Our firm continues to strengthen and grow, helping clients navigate complexity and make confident decisions as the forces reshaping how they run their businesses accelerate.”
Ruehlmann continued, “Charles, Traci and Galileo each bring strong pedigrees rooted in leadership, service and collaboration that will help guide our strategic direction and enhance the value we bring to clients.”
Charles is a partner in the Corporate and Private Equity team in the UK, advising leading private equity sponsors, portfolio companies and management teams based in the UK, Europe and North America on complex, high-value transactions across the investment lifecycle. His practice centres on sponsor-led buyouts and exits, cross-border M&A, carve-outs, joint ventures and public-to-private transactions, as well as structuring and negotiating management incentive arrangements. Known for his commercial approach and deal execution skills, Charles regularly supports clients on both platform acquisitions and add-on investments in the mid-market and beyond, delivering pragmatic, solutions-driven advice tailored to the priorities of sophisticated private capital investors.
Traci is the managing partner of the firm’s Columbus office and a nationally recognized trial lawyer and community leader. A passionate trial advocate, Traci has extensive experience nationwide, having successfully tried numerous cases to full defense verdicts across a wide range of disputes, including class actions, contracts, business torts, and catastrophic claims. She also counsels boards of directors and C-suites on complex employment issues. Currently, along with other chief executives in the community, Traci is an executive committee member of the non-profit economic development organization Columbus Partnership. She also serves as immediate past chair of the Experience Columbus Board of Directors, as a board trustee for Columbus State Community College, and as a board member for Downtown Columbus, Inc. and Future Ready Five. She also co-chairs the Ohio State Moritz College of Law National Advisory Counsel.
Galileo is the managing partner of the firm’s Milan office, focusing on international arbitration and energy law in the oil and gas sector. He represents national oil companies, governments, and state entities in upstream development and investment treaty arbitrations. Galileo has extensive experience handling disputes involving production sharing, joint operating agreements, concessions, licenses, and joint ventures. Galileo is admitted to practice in both Italy and New York and has held leadership positions in US law firms for many years.
They succeeded Gassan Baloul (Litigation, Washington DC), Oliver Geiss (Antitrust & Competition, Brussels) and Stacy Krumin (Financial Services and Real Estate, Tampa), who conclude their Board service.
Over the past 18 months, Squire Patton Boggs expanded its global practice with new offices in Baku and Astana while also adding senior talent across its core practices around the world. The firm has 48 offices across 25 countries.
